Description
Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Early Type 2 Diabetes: A Randomized Controlled Trial
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02014-10-01$366,920
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2014-10-01(start date) | $366,920 | — | Exenatide and Insulin Glargine Combination Therapy for the Preservation of Pancreatic Beta-cell Function in Ea… |
Related records · 4
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2013-2014-Q4-00492 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $1,297,418 | FY2015 |
| 236-2012-2013-Q2-00036 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $685,470 | FY2013 |
| 236-2011-2012-Q1-00812 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $804,195 | FY2012 |
| 236-2011-2012-Q2-00252 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $98,483 | FY2012 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2014-2015-Q2-00093 · retrieved 2026-11-14.